This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug, changing your diet or commencing any course of treatment.
Most important. A change in your diet, medicine, or dosage is likely to be necessary. Promptly consult your doctor or pharmacist.
How the interaction occurs:
Food, coffee, and orange juice can prevent your body from absorbing your osteoporosis medicine.
What might happen:
The amount of osteoporosis medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Take your osteoporosis medicine with water first thing upon arising for the day.If you are taking alendronate or risedronate, wait at least 30 minutes after taking your osteoporosis medicine before you eat anything, drink coffee or orange juice, or take other medicines.If you are taking clodronate or ibandronate, wait at least 60 minutes after taking your osteoporosis medicine before you eat anything, drink coffee or orange juice, or take other medicines.If you are taking etidronate or tiludronate, wait at least 2 hours after taking your osteoporosis medicine before you eat anything, drink coffee or orange juice, or take other medicines.Contact your healthcare professional (e.g., doctor or pharmacist) for more information.Your healthcare professionals may be aware of this interaction and may be monitoring you for it. Do not start, stop, or change your medicine or diet before checking with them first.
1.Fosamax (alendronate sodium) US prescribing information. Merck & Co., Inc. December, 2006.
2.Actonel (risedronate sodium) US prescribing information. Warner Chilcott (US), LLC April, 2013.
3.Loron (disodium clodronate) UK summary of product characteristics. Roche Products Limited October 25, 2006.
4.Boniva (ibandronate sodium) tablets US prescribing information. Roche Therapeutics, Inc. April, 2013.
5.Didronel (etidronate disodium) US prescribing information. Warner Chilcott (US), LLC April, 2013.
6.Skelid (tiludronate disodium) US prescribing information. Sanofi-Aventis U.S. LLC March, 2010.
7.Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995 Sep;58(3):288-98.
8.Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3 Suppl 3:S13-6.